Luminex this week provided investors with an update on its molecular diagnostics pipeline, including the integration of recently acquired GenturaDx and its sample-to-answer testing platform and the market uptake and opportunity for its xTAG Gastrointestinal Pathogen Panel.

Luminex also discussed the continuing market opportunity for its xTag Respiratory Viral Panel in the face of increasing competition, and provided an update on the pending launch of its xMAP NeoPlex 4 assay for newborn genetic disease screening.